Notícias

Bruker’s second quarter results prompted a significant negative market reaction, with shares declining sharply following the release. Management identified several factors behind the top-line shortfall, notably the ongoing weakness in U.S. academic and government funding and revenue timing delays in certain deep tech areas, such as semiconductor metrology tools. CEO Frank Laukien described the organic growth as “solid in many life science end markets,” but highlighted that softness in U.S. acade

Semiconductor metrology and energy research orders surge over 50% organically.

Bruker stock has had a strong run over the past year while the latest valuation work, including a Discounted Cash Flow (DCF) intrinsic value estimate and market multiple checks, still points to the shares trading at a discount to those fundamentals. Bruker has returned 57.6% over the past year, which puts extra focus on whether that share price move is now in line with the company’s underlying value. Recent acquisitions in life sciences, including the DISQVER metagenomic sequencing platform,...

Bruker Corporation’s Q2 2026 results, released on August 4, 2026, showed sales rising to US$838.5 million from US$797.4 million year over year, but a goodwill and intangible asset impairment charge of US$134.9 million and other items drove a net loss of US$52 million versus prior-year net income. The company reaffirmed a path to growth by guiding Fiscal Year 2026 revenues to US$3.54–US$3.57 billion, implying 3%–4% reported growth over 2025, while targeting cost savings and maintaining its...

Bruker (BRKR) just updated its 2026 revenue guidance alongside second quarter results, pairing a forecast of US$3.54b to US$3.57b in sales with a sizeable goodwill impairment and a reported quarterly net loss. See our latest analysis for Bruker. The sharp 1 day share price decline of 21.79% left Bruker trading at US$50.30, even though the 1 year total shareholder return is 57.62% and the 5 year total shareholder return is down 38.05%. This points to strong recent momentum but a weaker longer...

Moby summary of Bruker Corporation's Q2 2026 earnings call

Bruker (NASDAQ:BRKR) returned to organic revenue growth in the second quarter, posted stronger bookings across its Scientific Instruments business, and maintained its earnings outlook while adjusting guidance for currency and tax changes. Key Investor TakeawaysBruker (NASDAQ:BRKR) returned to organic revenue growth, with second-quarter revenue increasing 5.

Bruker (NASDAQ:BRKR) reported second-quarter revenue growth and expanded profitability as demand improved for scientific instruments, particularly in biopharma and several “deep tech” markets including semiconductor metrology, security detection and energy research. Second-quarter reported revenue

The headline numbers for Bruker (BRKR) give insight into how the company performed in the quarter ended June 2026, but it may be worthwhile to compare some of its key metrics to Wall Street estimates and the year-ago actuals.

Scientific instrument company Bruker (NASDAQ:BRKR) will be announcing earnings results this Tuesday before market open. Here’s what to look for.

Bruker’s 26.8% return over the past six months has outpaced the S&P 500 by 20.6%, and its stock price has climbed to $60.45 per share. This was partly thanks to its solid quarterly results, and the performance may have investors wondering how to approach the situation.

A company that generates cash isn’t automatically a winner. Some businesses stockpile cash but fail to reinvest wisely, limiting their ability to expand.

Bruker Corporation (NASDAQ:BRKR) is one of the 10 Best Brain-Computer Interface Stocks to Buy. On June 8, JPMorgan analyst Casey Woodring raised the price target on Bruker Corporation (NASDAQ:BRKR) to $65 from $45. The firm maintained an “Overweight rating” on the share. It updated the company model. Days earlier, on June 4, Bruker Corporation (NASDAQ:BRKR) […]

Shares of scientific instrument company Bruker (NASDAQ:BRKR). jumped 4.2% in the morning session after Barclays raised its price target to $60, and optimism grew around the company's latest medical instrument launches.

In early June 2026, Bruker expanded its microbiology diagnostics and high-resolution mass spectrometry portfolios, unveiling new MALDI Biotyper clinical capabilities, next‑generation NGS and sepsis workflows, and the timsMRMS platform for complex energy and materials research. These launches underline how Bruker is trying to link advanced analytical instruments with real-world applications in infectious disease management, sustainable fuels, and semiconductor and battery research. Now we’ll...

Bruker (NASDAQ:BRKR) is seeing stronger order momentum across several end markets, with semiconductor metrology, non-U.S. academic and government customers, and parts of its diagnostics business helping offset continued weakness in U.S. academic funding, a company representative said at a Jefferies

Bruker (BRKR) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.

Many small-cap stocks have limited Wall Street coverage, giving savvy investors the chance to act before everyone else catches on. But the flip side is that these businesses have increased downside risk because they lack the scale and staying power of their larger competitors.

The end of an earnings season can be a great time to discover new stocks and assess how companies are handling the current business environment. Let’s take a look at how Bruker (NASDAQ:BRKR) and the rest of the research tools & consumables stocks fared in Q1.

Bruker Corporation recently commissioned its BioSpec 18 Tesla preclinical MRI, the world’s highest-field horizontal-bore MRI system, at the Champalimaud Foundation in Lisbon, enabling ultra-high-resolution MRI and MRSI for advanced cancer and neuroscience research in preclinical models. This system’s ability to probe tissue microstructure and localized metabolism in vivo highlights how Bruker’s high-end imaging platforms are becoming embedded in cutting-edge translational oncology and brain...

The $10-50 price range often includes mid-sized businesses with proven track records and plenty of growth runway ahead. They also usually carry less risk than penny stocks, though they’re not immune to volatility as many lack the scale advantages of their larger peers.

Wall Street has issued downbeat forecasts for the stocks in this article. These predictions are rare - financial institutions typically hesitate to say bad things about a company because it can jeopardize their other revenue-generating business lines like M&A advisory.

A company that generates cash isn’t automatically a winner. Some businesses stockpile cash but fail to reinvest wisely, limiting their ability to expand.

Why Bruker (BRKR) is on investors’ radar today Bruker (BRKR) has drawn attention after a recent move in its share price, with the stock last closing at US$43.27. That puts fresh focus on how its current valuation lines up with fundamentals. See our latest analysis for Bruker. That latest move comes after a 18.91% 7 day share price return and a 15.11% 30 day share price return, although the share price is still down 10.06% year to date and the 3 year total shareholder return of 39.54% and 5...

In addition to the earnings release we issued earlier today, during today's conference call, we will be referencing a slide presentation that can be downloaded from the Events and Presentations section of Bruker's Investor Relations website. Before we begin, I would like to reference Bruker's safe harbor statement, which is shown on Slide 2 of the presentation. During this conference call, we will or may make forward-looking statements regarding future events and the financial and operational performance of the company that involve risks and uncertainties, including those related to our recent acquisitions, geopolitical risks, wars or blockades, market demand, tariffs, currency exchange rates, competitive dynamics or supply chains.

Bruker (NASDAQ:BRKR) reported first-quarter 2026 results that management said came in “well ahead of expectations,” even as the company continued to face pressure from U.S. academic demand weakness as well as tariff and currency headwinds. President and CEO Frank Laukien told investors that while y

Bruker (BRKR) delivered earnings and revenue surprises of +33.62% and +2.91%, respectively, for the quarter ended March 2026. Do the numbers hold clues to what lies ahead for the stock?

Scientific instrument company Bruker (NASDAQ:BRKR). announced better-than-expected revenue in Q1 CY2026, with sales up 2.7% year on year to $823.4 million. The company expects the full year’s revenue to be around $3.59 billion, close to analysts’ estimates. Its non-GAAP profit of $0.31 per share was 34.8% above analysts’ consensus estimates.

Bruker (BRKR) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

A few weeks ago, a research paper out of MIT (the college) crossed my desk that most investors would have ignored.It was about worms. Specifically, it was about a team that had successfully mapped the entire brain of a microscopic worm — every neuron, every connection. Then it laid out what it would take to scale that process from a worm… to a mouse… and eventually, to a human.InvestorPlace - Stock Market News, Stock Advice & Trading Tips Now, here’s where things get interesting for us. For deca